UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52

Benzinga · 3d ago
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the price target from $48 to $52.